Showing 11,141 - 11,160 results of 24,876 for search '(( e point decrease ) OR ( 100 ((we decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 0.99s Refine Results
  1. 11141
  2. 11142
  3. 11143
  4. 11144

    ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota by Sup Kim (6371849)

    Published 2021
    “…<p>The orphan nuclear receptor ESRRA (estrogen related receptor alpha) is critical in mitochondrial biogenesis and macroautophagy/autophagy function; however, the roles of ESRRA in intestinal function remain uncharacterized. Herein we identified that ESRRA acts as a key regulator of intestinal homeostasis by amelioration of colonic inflammation through activation of autophagic flux and control of host gut microbiota. …”
  5. 11145

    Data_Sheet_1_Modafinil’s effects on cognition and sleep quality in affectively-stable patients with bipolar disorder: a pilot study.pdf by Jessica M. Lipschitz (16927743)

    Published 2023
    “…</p>Methods<p>Twelve individuals with affectively-stable BD were recruited and randomized to a flexible dose of modafinil (100 to 200 mg/day) or placebo, adjunctive to a therapeutic dose of a mood stabilizer. …”
  6. 11146

    Table 1_Obstetric and perinatal outcomes in pregnancies conceived with donor versus partner sperm: a systematic review and meta-analysis.docx by Junjie Liu (193511)

    Published 2025
    “…Donor sperm was linked to better clinical pregnancy rates (RR 1.27, 95% CI 1.08–1.48) and decreased incidences of biochemical pregnancy (RR 0.85, 95% CI 0.81–0.88), miscarriage (RR 0.91, 95% CI 0.84–1.00), very preterm birth (RR 0.88, 95% CI 0.80–0.96), and very low birth weight (RR 0.89, 95% CI 0.81–0.98) compared with partner sperm. …”
  7. 11147

    Opposite regulation of <i>chd</i> by <i>hairy2a</i> or <i>braEnR</i> depending on the D by Cecilia E. Aguirre (287180)

    Published 2013
    “…<i>Chd</i> expression decreased in 88% or 100% of dorsalised embryos that were injected with 1 ng of <i>braEnR</i> (<i>braEnR</i>/LiCl; n = 41) or of <i>hairy2a</i> mRNAs (<i>hairy2a</i>/LiCl, n = 23), respectively.…”
  8. 11148

    Table_3_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  9. 11149

    Table_4_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  10. 11150

    Table_6_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  11. 11151

    Table_2_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  12. 11152

    Table_7_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  13. 11153

    Table_1_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  14. 11154

    Table_5_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  15. 11155
  16. 11156

    Table_1_Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study.docx by Eun-Gyeong Lee (627417)

    Published 2023
    “…The OS rate in SPBC decreased significantly with advanced stage and older age.…”
  17. 11157

    Structure of the IHE model. by Dunming Xiao (20531096)

    Published 2025
    “…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”
  18. 11158

    Results of base case. by Dunming Xiao (20531096)

    Published 2025
    “…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”
  19. 11159

    Clinical efficacy data. by Dunming Xiao (20531096)

    Published 2025
    “…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”
  20. 11160

    Cost-effectiveness acceptable curve. by Dunming Xiao (20531096)

    Published 2025
    “…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”